BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), today reported its financial results for the year ended February 28, 2023. The Company is pleased to be able to report on its results for the fiscal year 2023 which ended February 28, 2023. 2023 Financial Information: Fiscal Year: February 28 2023 February 28 2022 % Change Revenue CAD$ 718,298 CAD$ 1,751,916 -59.0% Operating expenses 4,180,819 5,780,138 -27.5 Non-cash ch
MMP News Author
Source link